Radiopharm Theranostics Limited targets oncology with radiotherapeutics like Lu-RAD204 for NSCLC. Key 2025 data signals ...

Single IV administration of tau silencing gene therapy VY1706 significantly reduced tau mRNA and protein levels, with broad brain distribution ...

Single IV administration of tau silencing gene therapy VY1706 significantly reduced tau mRNA and protein levels, with broad brain distribution and liver de-targeting, in NHP study - - Preclinical muri ...

Preclinical presentation highlights key, modality specific, pharmacological differentiations of VG-3927 - - First presentation of topline ...

The llama-derived single-domain antibodies are smaller than human antibodies and can attach to parts of a virus that are difficult to access for the human immune system ...

SON-1010 is being studied as a combination therapy with trabectedin (Yondelis®), the first FDA-approved treatment for two types of advanced soft tissue sarcoma after failure of standard chemotherapy, ...

The US Court of Appeals for the Federal Circuit found a Jepson claim unpatentable where the specification did not provide adequate written ...

ProMIS expects to report six-month interim results from PRECISE-AD in the first half of 2026, with topline results ...

LEXINGTON, MA, USA I March 31, 2025 I Keros Therapeutics, Inc. (“Keros”) (Nasdaq: KROS), a clinical-stage biopharmaceutical company focused on developing and ...

Dysfunctional Family. A family tree of tau folds now incorporates two new structures—P301L, P301T (bottom)—and fills in ...

“Automation has already been heavily utilized in many aspects of mAb manufacturing, such as process control, monitoring, and ...